{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:39:01Z","timestamp":1792766341626,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011621","name":"Emory University Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019621","name":"Ascentage Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403748"],"award-info":[{"award-number":["82403748"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217962","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:12:07Z","timestamp":1753888327000},"page":"217962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib"],"prefix":"10.1016","volume":"632","author":[{"given":"Guangzhi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1447-3653","authenticated-orcid":false,"given":"Yunfu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9201-1492","authenticated-orcid":false,"given":"Weijia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-8826","authenticated-orcid":false,"given":"Shi-Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217962_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217962_bib2","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.217962_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104762","article-title":"Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations","volume":"212","author":"Gomez-Randulfe","year":"2025","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.canlet.2025.217962_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.resinv.2025.04.021","article-title":"Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations","volume":"63","author":"Miyata","year":"2025","journal-title":"Respiratory Investigation"},{"key":"10.1016\/j.canlet.2025.217962_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091515","article-title":"Non-small cell lung cancer with epidermal growth factor receptor (EGFR) common mutations: new strategies","volume":"17","author":"Stanzione","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.217962_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-1912","article-title":"Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer","author":"Blaquier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2025.217962_bib8","first-page":"82","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","author":"Du","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2025.217962_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26072957","article-title":"Strategies to overcome resistance to osimertinib in EGFR-mutated lung cancer","volume":"26","author":"Romaniello","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.217962_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.18632\/oncoscience.544","article-title":"Taking action early to manage emergence of acquired resistance to osimertinib or other third generation EGFR inhibitors","volume":"8","author":"Ma","year":"2021","journal-title":"Oncoscience"},{"key":"10.1016\/j.canlet.2025.217962_bib11","first-page":"1","article-title":"Managing acquired resistance to third-generation EGFR tyrosine kinase inhibitors through Co-Targeting MEK\/ERK signaling","volume":"12","author":"Yu","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.217962_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pccm.2022.10.001","article-title":"Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors","volume":"1","author":"Sun","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"10.1016\/j.canlet.2025.217962_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071590","article-title":"Drug tolerance to EGFR tyrosine kinase inhibitors in lung cancers with EGFR mutations","volume":"10","author":"Suda","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2025.217962_bib14","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","article-title":"Drug-tolerant persister cells in cancer therapy resistance","volume":"82","author":"Dhanyamraju","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217962_bib16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217962_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41388-022-02200-5","article-title":"Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, bax activation, or both","volume":"41","author":"Ma","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217962_bib18","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-17-1574","article-title":"Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEK\/ERK-Dependent bim and Mcl-1 degradation","volume":"23","author":"Shi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217962_bib20","first-page":"3788","volume":"126","author":"Gu","year":"2020"},{"key":"10.1016\/j.canlet.2025.217962_bib21","first-page":"4931","article-title":"Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells","volume":"57","author":"Sun","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217962_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2020.09.023","article-title":"Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib","volume":"150","author":"Gu","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2025.217962_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-15-0063","article-title":"Combined EGFR\/MEK inhibition prevents the emergence of resistance in EGFR mutant lung cancer","author":"Tricker","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217962_bib25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","article-title":"Hallmarks of cellular senescence","volume":"28","author":"Hernandez-Segura","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2025.217962_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","article-title":"Cellular senescence: defining a path forward","volume":"179","author":"Gorgoulis","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217962_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2024.100102","article-title":"Brief guide to senescence assays using cultured Mammalian cells","volume":"47","author":"Kang","year":"2024","journal-title":"Mol. Cells"},{"key":"10.1016\/j.canlet.2025.217962_bib28","article-title":"Biomarkers of cellular senescence and aging: current State-of-the-Art, challenges and future perspectives","volume":"8","author":"Muthamil","year":"2024","journal-title":"Adv Biol-Ger"},{"key":"10.1016\/j.canlet.2025.217962_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.13223","article-title":"Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer","volume":"83","author":"Brown","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217962_bib30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11684-022-0951-0","article-title":"Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors","volume":"16","author":"Sun","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.canlet.2025.217962_bib31","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-18-0304","article-title":"Increased synthesis of MCL-1 protein underlies initial survival of EGFR-mutant lung cancer to EGFR inhibitors and provides a novel drug target","volume":"24","author":"Song","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib32","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"23","author":"Domina","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217962_bib33","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1158\/0008-5472.CAN-08-0579","article-title":"Down-regulation of myeloid cell leukemia-1 through inhibiting erk\/pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer","volume":"68","author":"Ding","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217962_bib34","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2025.217962_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108211","article-title":"MCL-1 as a potent target for cancer: recent advancements, structural insights and SAR studies","volume":"156","author":"Sharma","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.canlet.2025.217962_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1226289","article-title":"Targeting MCL-1 protein to treat cancer: opportunities and challenges","volume":"13","author":"Tantawy","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.217962_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-025-01481-z","article-title":"The BCL-2 protein family: from discovery to drug development","author":"Croce","year":"2025","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.217962_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117168","article-title":"Chemical dissection of selective myeloid leukemia-1 inhibitors: how they were found and evolved","volume":"283","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2025.217962_bib39","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1021\/acs.jmedchem.3c01998","article-title":"Targeting myeloid Leukemia-1 in cancer therapy: advances and directions","volume":"67","author":"Deng","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:00:15Z","timestamp":1772784015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"alternative-id":["S0304383525005312"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217962","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217962"}}